Tenaya Therapeutics, Inc. Common Stock
TNYATenaya Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious, life-threatening genetic diseases, particularly those affecting the heart. Founded with the aim of transforming the treatment landscape, Tenaya leverages advanced genetics, stem cell biology, and disease modeling to identify and develop innovative medicines. The company's approach centers on understanding the underlying mechanisms of genetic disorders and translating this knowledge into targeted therapies to improve patient outcomes.
Company News
Tenaya Therapeutics shares surged 31.20% following a research collaboration agreement with Alnylam Pharmaceuticals focused on discovering genetic targets for cardiovascular disease treatments. Tenaya will validate up to 15 gene targets and receive up to $10 million in upfront payments with potential milestone payments reaching $1.13 billion. Desp...
Tenaya Therapeutics announced promising interim clinical results for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy, showing improved biomarkers, reduced hypertrophy, and manageable safety profile in early-stage trials.
Tenaya Therapeutics shared interim data from its MyClimb study on pediatric patients with MYBPC3-associated hypertrophic cardiomyopathy, revealing significant risks and disease progression patterns across different genetic inheritance groups.
The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safet...
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role
